HomeGreater Than Icon
Dr Reddys Laboratories LtdGreater Than Icon
Dr Reddys Laboratories Ltd Financials
Company Logo

Dr Reddys Laboratories Ltd Financial Statement

Dr Reddys Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue6059.00
Operating Expense3888.20
Net Profit1417.20
Net Profit Margin23.39
Earning Per Share85.10
EBIDTA2140.70
Effective Tax Rate21.49

Dr Reddys Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual19,483.80
Operating Expenses Annual13,557.40
Operating Profit Annual6,788.70
Interest Annual21.80
Depreciation758.10
Net Profit Annual4,342
Tax Annual1,449.30

Dr Reddys Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning112.30
Cash Flow from Operations3,449.70
Cash Flow from Investing-3,428.70
Cash Flow from Financing68.10
Cash Flow at the End201.40

Dr Reddys Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)34.84
PBIT Margin (%)29.84
PBT Margin (%)28.47
Net PROFIT Margin (%)22.29
Return On Networth / Equity (%)19.42
Return On Networth /Employed (%)25.40
Return On Assets (%)18.94
Total Debt / Equity (X)0.02
Asset Turnover Ratio (%)0.85

Dr Reddys Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual7,628.20
Total Current Assets Annual17,815.90
Non Current Assets Annual12,543.40
Total Shareholders Funds Annual24,240.80
Total Assets Annual30,359.30

Dr Reddys Laboratories Ltd Earning Calls

EPS (INR)

Expected

83.48

Reported

83.61

Surprise

0.16%

Mar 2024

EPS beaten by 0.16%

Dec 2023

EPS beaten by 0.17%

Sep 2023

EPS beaten by 0.18%

Get Your FAQs Right

As of Nov 5, 2024, Dr Reddys Laboratories Ltd has a market capitalization of 1,02,679.14 Cr. Value Research classifies it as a Large-Cap company.
Yes, Dr Reddys Laboratories Ltd is debt-free with a debt-to-equity ratio of 0.03.
In FY 2023 , Dr Reddys Laboratories Ltd recorded a total revenue of approximately 19,404.10 Cr marking a significant milestone in the company's financial performance.
Dr Reddys Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.2% annually, respectively..
Dr Reddys Laboratories Ltd's current PE ratio is 23.65.
Dr Reddys Laboratories Ltd's ROCE averaged 17.6% from the FY ending March 2022 to 2024, with a median of 18.8%. It peaked at 23.1% in March 2024, reflecting strong capital efficiency over the period..
Dr Reddys Laboratories Ltd's latest EBIT is Rs. 5,813.10 Cr, surpassing the average EBIT of Rs. 3,985.93 Cr over the 5 years..